| Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. | |
| | |
MedLine Citation:
|
PMID: 10861457 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The recombinant immunotoxins anti-Tac(Fv)-PE38 (LMB-2), targeting the interleukin-2 receptor alpha subunit (IL-2Ralpha, Tac or CD25), and RFB4(dsFv)-PE38 (BL22), targeting CD22, are being evaluated in clinical trials as treatment for hematologic malignancies. The toxin moiety Pseudomonas exotoxin A (PE) of these recombinant molecules leads to the arrest of protein synthesis due to inactivation of elongation factor 2. Here, we provide evidence that cell lines derived from patients with hematologic malignancies react to immunotoxins not only with inhibition of protein synthesis but also with characteristic hallmarks of apoptosis such as caspase activation, cleavage of the "death substrate poly(ADP)-ribose polymerase and DNA laddering. Anti-Tac(Fv)-PE38 leads to a 10-fold increase in the cleavage of the fluorescent substrate DEVD-AFC, suggesting that a caspase-3-like enzyme is involved. This was verified by cleavage of caspase-3 (CPP32). MT1 cells exhibited DNA laddering after treatment with immunotoxin, which was reversed by pre-treatment with the protease inhibitor zVAD-fmk. This caspase inhibitor led to an at least 5-fold improvement in cell viability without altering inhibition of protein synthesis. Interestingly, HUT-102 cells did not undergo programmed cell death after exposure to immunotoxins that kill these cells. We conclude that immunotoxins may be valuable in the treatment of cancers that are resistant toward apoptosis because their targeted killing is often facilitated by, but not completely dependent on, programmed cell death. Int. J. Cancer 87:86-94, 2000. Published 2000 Wiley-Liss, Inc. |
| | |
Authors:
|
A Keppler-Hafkemeyer; R J Kreitman; I Pastan |
Related Documents
:
|
18515717 - Extensive apoptosis and abnormal morphogenesis in pro-caspase-3 transgenic zebrafish du... 11313717 - Zinc-mediated regulation of caspases activity: dose-dependent inhibition or activation ... 10899937 - The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an eff... 15904897 - Reactive oxygen species-mediated induction of apoptosis by a plant alkaloid 6-methoxydi... 8971027 - Apoptosis and t-cell depletion during feline infectious peritonitis. 10865077 - Increased cerebrospinal fluid fas (apo-1) levels in alzheimer's disease. relationship w... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: International journal of cancer. Journal international du cancer Volume: 87 ISSN: 0020-7136 ISO Abbreviation: Int. J. Cancer Publication Date: 2000 Jul |
Date Detail:
|
Created Date: 2000-07-13 Completed Date: 2000-07-13 Revised Date: 2007-07-24 |
Medline Journal Info:
|
Nlm Unique ID: 0042124 Medline TA: Int J Cancer Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 86-94 Citation Subset: IM |
Affiliation:
|
Laboratory of Molecular Biology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amino Acid Chloromethyl Ketones
/
pharmacology Antibodies Antigens, CD / immunology Antigens, CD22 Antigens, Differentiation, B-Lymphocyte / immunology Apoptosis / drug effects* Burkitt Lymphoma / enzymology, therapy Caspase 3 Caspases / metabolism Cell Adhesion Molecules* Cell Survival / drug effects Coumarins / pharmacology DNA Fragmentation / drug effects Dose-Response Relationship, Drug Hematologic Neoplasms / therapy* Immunoblotting Immunotoxins / adverse effects*, therapeutic use* Lectins* Leucine / metabolism Leukemia / enzymology, therapy Lymphoma, T-Cell / enzymology, therapy Oligopeptides / pharmacology Protease Inhibitors / pharmacology Recombinant Proteins / metabolism Tetrazolium Salts / pharmacology Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium; 0/Amino Acid Chloromethyl Ketones; 0/Antibodies; 0/Antigens, CD; 0/Antigens, CD22; 0/Antigens, Differentiation, B-Lymphocyte; 0/Cell Adhesion Molecules; 0/Coumarins; 0/Immunotoxins; 0/Lectins; 0/Oligopeptides; 0/Protease Inhibitors; 0/Recombinant Proteins; 0/Tetrazolium Salts; 0/antitac(FV)-PE38 recombinant immunotoxin; 0/aspartyl-glutamyl-valyl-aspartyl-7-amino-4-trifluoromethylcoumarin; 0/benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 61-90-5/Leucine; EC 3.4.22.-/Caspase 3; EC 3.4.22.-/Caspases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase...
Next Document: Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murin...